Texas Children's Hospital and Baylor College of Medicine are working on a new COVID-19 vaccine candidate. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Two major health care institutions in Houston — Texas Children's Hospital and the Baylor College of Medicine — are a step closer to rolling out what they dub the "people's vaccine" for COVID-19.

The two institutions, along with India-based vaccine and pharmaceutical company Biological E Ltd., have gained approval to move ahead this month with Phase III clinicals trials in India of a COVID-19 vaccine candidate called Corbevax. The Texas Children's Hospital Center for Vaccine Development developed the vaccine's protein antigen, which was licensed from the Baylor College of Medicine's BCM Ventures commercialization arm.

Unlike COVID-19 vaccines in the U.S., Corbevax contains the so-called "spike protein" from the surface of the novel coronavirus. Once that protein is injected via a vaccine, the body is supposed to begin building immunity against the protein and thereby prevent serious illness.

Experts envision Corbevax being a readily available weapon in the global fight against the COVID-19 pandemic, thanks to the simple vaccine platform (like the one used to prevent Hepatitis B) and the ability to store the vaccine in normal refrigerated settings. The targets of this vaccine are children and mothers.

"In the midst of India's public health crisis, it is our hope that our Texas Children's and Baylor COVID-19 vaccine can be released for emergency authorization in India and in all countries in need of essential COVID-19 vaccinations," Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development, says in a June 9 news release.

India has reported more than 29 million cases of COVID-19, causing 354,000 deaths. The country's COVID-19 surge reached its peak in May.

"The vaccines currently available cannot be manufactured quick enough to meet supply shortages in low-income countries," Hotez says. "Our vaccine is truly 'the people's vaccine,' created to serve the most marginalized and underserved populations that are hardest hit by this pandemic. This is the vaccine that could be used to vaccinate the world."

In the Phase III trial, the two-dose Corbevax vaccine will be administered to about 1,200 people age 18 to 80 at 15 sites in India. A larger global study of Corbevax is in the works.

According to India.com, Corbevax could be the most affordable COVID-19 vaccine available in the nation of nearly 1.37 billion people, costing close to $7 for a two-dose regimen. The Indian government already has preordered 300 million doses of Corbevax, which has shown promise in Phase I and Phase II trials. The Phase II trial ended in April.

If the Phase III trial goes as planned, doses could be widely administered as soon as August. Biological E initially plans to produce 75 million to 80 million doses per month, according to media reports. The Indian company foresees manufacturing at least 1 billion doses by the end of 2022.

Houston can expect the new vaccine in the next week. WPA Pool / Getty Images

Here's when Houston can expect the Johnson & Johnson COVID-19 vaccine

coming soon

Texas can expect to receive the first 200,000 doses of the coveted Johnson & Johnson COVID-19 vaccine this week. The company announced that it has started the rollout process on March 1 — after the FDA approved its Emergency Use Authorization.

The Center for Disease Control gave the developer, Janssen Pharmaceutical, the final greenlight Sunday, February 28.

What does that mean for Houston? Mayor Sylvester Turner said the Houston Health Department is also anticipated to be on the list to receive Johnson & Johnson doses within the next seven days.

"That will be a game changer," Turner said at an event on February 28 afternoon. "There will be more vaccines available in a shorter period of time. We anticipate that we will probably get a shipment in sometime this week that will add to the Pfizer [doses] that we are using at NRG."

Turner said other clinics with the Houston Health Department have been administering the Moderna vaccine.

The Johnson & Johnson vaccine does have noticeable differences from the Pfizer and Moderna vaccines, experts said.

The MRNA vaccines each require two shots which are usually delivered weeks apart and stored in freezers. The Johnson & Johnson vaccine is a single shot that can be stored in a refrigerator for up to three months at 35 to 46 degrees.

However, Johnson & Johnson does not have as much of the COVID-19 vaccine produced as originally anticipated. ABC13 confirmed 3.9 million doses will be shipped out across the country this week. Johnson & Johnson announced roughly an additional 16 million doses by the end of the month.

"In the next few weeks, it won't have much of any impact because they only have at least three or four million doses available, and that's disappointing news," says Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine. "In the longer term, over the next few months, it's really important because we need a greater vaccine supply. We are not going to get there with the two MRNA vaccines. We need probably up to five different vaccines in order to vaccinate the American people."

Recently, there has been a decline in COVID-19 hospitalizations and COVID-19 cases reported statewide. As of Sunday, about 5,700 Texans are in the hospital due to COVID-19, which is half the number of hospitalization in the beginning of the month.

Infectious disease epidemiologist Dr. Catherine Troisi says it's important for people to not let their guard down and that people should get tested if they have been in a high-exposure situation, or if they have been in direct contact with someone who has tested positive.

"Get vaccinated, don't worry about what vaccine it is," Dr. Troisi notes. "It's true that unfortunately there are not as many doses right now of the Johnson & Johnson vaccine as we have hoped, but the company is saying that by the end of June, they will have a 100 million doses, and that's into 100 million people because you don't need two doses.

"So, we expect to have 600 million doses of the other two vaccines, that's 300 million people," she continues. "That should be enough for everyone who wants the vaccine to be able to get it. With one caveat and that is as of right now we do not have a vaccine for children under age 16. Those trials are going on, hopefully as we go throughout the year there will be a vaccine licensed to 12 year-olds and then maybe going down to 8 years or older."

For more details on the Johnson & Johnson vaccine rollout, visit the FDA's website.

---

This article originally ran on CultureMap. For more on this story, visit our news partner ABC13.

Health care leaders joined a virtual panel to discuss the effects of COVID-19 and more. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Overheard: Houston health care experts sound off on how tech and COVID-19 have affected the industry

eavesdropping in houston

There has been an undeniable paradigm shift in the health care industry due to COVID-19 as well as the growth of technology. A group of professionals sat down to discuss what in particular has changed for the industry as a whole as well as at local institutions.

At a panel for Venture Houston, a two-day conference put on by the HX Venture Fund on February 4th and 5th, a few health care professionals weighed in on all the changes to the industry for the startups, investors, corporations, and more who attended the virtual event. Here are some significant overheard moments from the virtual panel — Thinking Past a COVID World.

“For most of health care, this last year has been probably five years of rapid cycle re-innovation and movement forward — particularly in the digital realm.”

Marc Boom, president and CEO of Houston Methodist. From rapid adoption of telemedicine to developing a COVID-19 vaccine in less than a year, health care has seen rapid growth. However, there's fine tuning still needed, Boom continues.

"At the end of the day there's only so much we can do virtually," he adds.

“The most incredible thing was how the vaccines got developed so quickly.”

Chris Rizik, CEO of Renaissance Venture Partners. A large portion of the industry wasn't excited about RNA vaccines, but the COVID-19 vaccines might have changed some minds. It took 11 months to get it out into the world, but 10 of that was purely regulatory, he adds.

"One of the sustaining changes of the COVID-19 pandemic is I think RNA vaccines are here to stay."

​— Paul Klotman, executive dean of Baylor College of Medicine. Klotman adds that the vaccine's trials were so impressively quick because there were just so many COVID patients sick and eligible to enroll.

“I think one of the things the TMC institutions did really well was to decide really early on was to share data.”

Boom says, adding that the TMC represents around 70 percent of Houston's adults and around 90 percent of the city's pediatric patients. This opportunity for data is "one of the most robust sources of real-time data."

"Yes, you're going to compete clinically, but there's a lot of collaboration to be done especially during a pandemic," Boom says of the TMC's member organizations prioritizing collaboration with data sharing.

“Houston has done better than almost all major metropolitan areas because we have came together as a city and a community.”

Klotman says, adding that the vast patient base the TMC is key.

"There's a huge opportunity here for early biotech development," he says. "Because there are so many patients, there are huge opportunities to do new trials."

“The real challenge is for investors to be in tune to know what’s here to stay, and to invest around that."

Rizik says, adding that 2020 was the biggest year for health care investment with more money going into deals, rather than more deals occuring.

“We’re seeing a huge uptick in people interested in health professions, thanks to COVID.”

Boom says of the industry's workforce, which has usually been hard to recruit and grow.

“The medical school communities are all racing to change the way we teach and the kind of information we teach.”

Klotman says of the future of the workforce.

“Unlike most industries, technology is tended to be cumbersome in health care.

​— Boom says adding that new technology means added costs and slowed down processes that can't replace the human touch. Houston Methodist is looking for innovations that don't take health care professionals away from patients.

“If there’s anything this last year has shown us is that as fast as we thought we were going, we need to go faster. We’re excited to work with companies with great ideas.”

— Boom says of the future of tech in health care. "I think we're on a very transformational era in digital health right now — but there's a lot of work to be done still."

NASA has renewed its support for Baylor College of Medicine's Translational Research Institute for Space Health. Photo courtesy of NASA

Houston research organization receives renewal from NASA and millions in funding for space health projects

new funding

Baylor College of Medicine's Translational Research Institute for Space Health, or TRISH, was granted renewal from NASA this week, which will allow the organization to continue to conduct biomedical research geared at protecting astronauts in deep space through 2028.

According to a statement, NASA reviewed TRISH in December 2020 ahead of the five year mark of its cooperative agreement with BCM's Center for Space Medicine. NASA opted to continue the partnership and now TRISH will receive additional funding of up to $134.6 million from 2022 to 2028.

"NASA has received outstanding value from our bold approach to sourcing and advancing space health research and technologies," institute director Dorit Donoviel, said in a statement. "We are proud to be NASA's partner in its human space exploration mission and to be supporting the research necessary to create new frontiers in healthcare that will benefit all humans."

The institute will focus its efforts on Mars exploration missions in the next six years and has been given three main objectives, according to the release:

  • To build strategic partnerships that will increase the volume of available biometric data on the impact of space travel on health and astronaut performance
  • To build a digital platform that simulates the spaceflight environment and will allow researchers to model and test new health technologies on Earth
  • To develop tissue chip technology that will allow astronauts to place a variety of human cells in lunar orbit during the NASA Artemis research missions to track the effects of space radiation and microgravity on humans

Since TRISH was founded in 2016 it has led the charge in space health research and has partnered with and provided grants to an array of innovative startups to do so.

In 2020 is granted Houston-based Z3VR $50,000 to explore the ways virtual reality can boost physical and mental health among astronauts and it has funded several projects surrounding space radiation levels.

At the time of 2020 review, TRISH had developed and transitioned 34 completed astronaut health and protection projects to NASA and had connected 415 first-time NASA researchers with opportunities to develop space health solutions.

From opioid research to plastics recycling, here are three research projects to watch out for in Houston. Photo via Getty Images

Here are 3 breakthrough innovations coming out of research at Houston institutions

Research Roundup

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research projects, we look into studies on robotics advancing stroke patient rehabilitation, the future of opioid-free surgery, and a breakthrough in recycling plastics.

The University of Houston's research on enhancing stroke rehabilitation

A clinical trial from a team at UH found that stroke survivors gained clinically significant arm movement and control by using an external robotic device powered by the patients' own brains. Image via UH.edu

A researcher at the University of Houston has seen positive results on using his robotics on stroke survivors for rehabilitation. Jose Luis Contreras-Vidal, director of UH's Non-Invasive Brain Machine Interface Systems Laboratory, recently published the results of the clinical trial in the journal NeuroImage: Clinical.

The testing proved that most patients retained the benefits for at least two months after the therapy sessions ended, according to a press release from UH, and suggested even more potential in the long term. The study equipped stroke survivors who have limited movement in one arm with a computer program that captures brain activity to determine the subject's intentions and then works with a robotic device affixed to the affected arm, to move in response to those intentions.

"This is a novel way to measure what is going on in the brain in response to therapeutic intervention," says Dr. Gerard Francisco, professor and chair of physical medicine and rehabilitation at McGovern Medical School at The University of Texas Health Science Center at Houston and co-principal investigator, in the release.

"This study suggested that certain types of intervention, in this case using the upper robot, can trigger certain parts of brain to develop the intention to move," he continues. "In the future, this means we can augment existing therapy programs by paying more attention to the importance of engaging certain parts of the brain that can magnify the response to therapy."

The trial was funded by the National Institute of Neurological Disorders and Stroke and Mission Connect, part of the TIRR Foundation. Contreras-Vidal is working on a longer term project with a National Science Foundation grant in order to design a low-cost system that would allow people to continue the treatments at home.

"If we are able to send them home with a device, they can use it for life," he says in the release.

Baylor College of Medicine's work toward opioid-free surgery

A local doctor is focused on opioid-free options. Photo via Getty Images

In light of a national opioid crisis and more and more data demonstrating the negative effects of the drugs, a Baylor College of Medicine orthopedic surgeon has been working to offer opioid-free surgery recovery to his patients.

"Thanks to a number of refinements, we are now able to perform hip and knee replacements, ranging from straightforward to very complex cases, without patients requiring a single opioid pill," says Dr. Mohamad Halawi, associate professor and chief quality officer in the Joseph Barnhart Department of Orthopedic Surgery, in a press release.

"Pain is one of patients' greatest fears when undergoing surgery, understandably so," Halawi continues. "Today, most patients wake up from surgery very comfortable. Gone are the days of trying to catch up with severe pain. It was a vicious cycle with patients paying the price in terms of longer hospitalization, slower recovery and myriad adverse events."

Halawi explains that his work focuses on preventative measures ahead of pain occurring as well as cutting out opioids before surgery.

"Opioid-free surgery is the way of the future, and it has become a standard of care in my practice," he says. "The ability to provide safer and faster recovery to all patients regardless of their surgical complexity is gratifying. I want to make sure that pain is one less thing for patients to worry about during their recovery."

Rice University's breakthrough on recycling plastics

A team of scientists have found a use for a material that comes out of plastics recycling. Photo via Rice.edu

Houston scientists has found a new use for an otherwise useless byproduct that comes from recycling plastics. Rice University chemist James Tour has discovered that turbostratic graphene flakes can be produced from pyrolyzed plastic ash, and those flakes can then be added to other substances like films of polyvinyl alcohol that better resist water in packaging and cement paste and concrete, as well as strengthen the material.

"This work enhances the circular economy for plastics," Tour says in a press release. "So much plastic waste is subject to pyrolysis in an effort to convert it back to monomers and oils. The monomers are used in repolymerization to make new plastics, and the oils are used in a variety of other applications. But there is always a remaining 10% to 20% ash that's valueless and is generally sent to landfills.

Tour's research has appeared in the journal Carbon. The co-authors of the study include Rice graduate students Jacob Beckham, Weiyin Chen and Prabhas Hundi and postdoctoral researcher Duy Xuan Luong, and Shivaranjan Raghuraman and Rouzbeh Shahsavari of C-Crete Technologies. The National Science Foundation, the Air Force Office of Scientific Research and the Department of Energy supported the research.

"Recyclers do not turn large profits due to cheap oil prices, so only about 15% of all plastic gets recycled," said Rice graduate student Kevin Wyss, lead author of the study. "I wanted to combat both of these problems."

The five scientists represent five different academic institutions in Houston. Photo via Getty Images

5 Houston inventors named fellows of a prestigious international program

top researchers

The National Academy of Inventors has recognized 175 scientists from across the world as NAI Fellows — and five of those inventors are based at Houston institutions.

The program honors academic inventors who, according to NAI, "have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society."

The five Houston inventors join the ranks of a group of individuals who have generated over 13,000 licensed technologies and companies, and created more than 19 million jobs, according to the announcement.

These are the scientists from Houston organizations:

  • Ananth Annapragada of Baylor College of Medicine is professor of radiology and obstetrics and gynecology, vice chief of research and director of basic research at Baylor College of Medicine and Texas Children's Hospital as well as a member of the Dan L Duncan Comprehensive Cancer Center.
  • Ronald Biediger of the Texas Heart Institute is associate director of chemistry, Wafic Said Molecular Cardiology Research Laboratories and leading a group of chemists developing small molecule integrin antagonists and agonists for use as therapies, or as adjuncts to cell based therapies, for heart, lung and vascular disease
  • Mark Clarke of the University of Houston is associate provost for faculty development and faculty affairs at the University of Houston.
  • Ashutosh Sabharwal of Rice University is professor and Ph.D of electrical engineering and was named Fellow of the Institute of Electrical and Electronics Engineers in 2014 for contributions to the theory and experimentation of wireless systems and networks.
  • Jia Zhou of The University of Texas Medical Branch is professor in the Department Pharmacology and Toxicology focusing on drug discovery of bioactive molecules to probe biological systems or act as potential therapeutic agents in neuroscience, cancer/inflammation, infectious diseases, and other human conditions.

The new class of inventors will be inducted on June 8 at the 10th Annual Meeting of the National Academy of Inventors in Tampa, Florida.

These scientists have already established dozens of patents between the five of them across fields and industries. Clarke specifically holds 13 U.S. patents, seven NASA technology innovation awards, and has founded two life science startup companies to commercialize his technologies, according to a news release from UH.

"Most faculty inventors, including myself, do not begin their research careers focused on creating or commercializing new technologies, nor do they usually know where to start when presented with such an opportunity," Clarke says in the release. "Helping faculty members and students transition fundamental discoveries into commercially valuable technologies and products is not only a key part of our mission as a Tier One research university, it is critical to our region's economic prosperity and ensuring that the U.S. remains competitive in an innovation-driven global economy."

From BCM, Annapragada holds 15 patents in the United States and close to 100 worldwide. The majority of his patents are in next generation imaging technologies, CT vascular imaging, and MR molecular imaging, according to a BCM release, and Annapragada is the founder of two active startup companies — Alzeca Inc. and Sensulin LLC.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston again recognized as a top major city of the future

Bragging rights

Houston, the future looks bright.

A new study from the fDi Intelligence division of the Financial Times places Houston at No. 7 among the top major cities of the future for 2021-22 across North, South, and Central America. Among major cities in the Americas, Houston appears at No. 3 for business friendliness and No. 4 for connectivity.

"Houston is known as one of the youngest, fastest-growing, and most diverse cities anywhere in the world. I am thrilled that we continue to be recognized for our thriving innovation ecosystem," Houston Mayor Sylvester Turner is quoted as saying in the fDi study.

Toronto leads the 2021-22 list of the top major cities in the Americas, followed by San Francisco, Montreal, Chicago, and Boston.

The rankings are based on data in five categories:

  • Economic potential
  • Business friendliness
  • Human capital and lifestyle
  • Cost effectiveness
  • Connectivity

Houston's no stranger to the list. Last year, the city ranked No. 3 on the same study, and in 2019, claimed the No. 5 spot.

"The fact that Houston consistently ranks among the top markets for foreign direct investment speaks to our region's connectivity and business-friendly environment," says Susan Davenport, chief economic development officer at the Greater Houston Partnership. "Many of the industry sectors we target for expansion and relocation in Houston are global in nature — from energy 2.0 and life sciences to aerospace and digital tech. The infrastructure and diverse workforce that make these prime growth sectors for us among domestic players are equally attractive to international companies looking to establish or strengthen ties in the Americas."

International trade is a cornerstone of the Houston area's economy. In 2020, the region recorded $129.5 billion in exports, according to the Greater Houston Partnership. China ranked as the region's top trading partner last year, followed by Mexico, Brazil, Korea, Germany, the Netherlands, India, Japan, the United Kingdom, and Italy.

Houston's role as a hub for foreign trade and international business "is likely to support the region's economic recovery in the months and years ahead," the partnership noted in May.

"We talk often of Houston as a great global city — one that competes with the likes of London, Tokyo, São Paulo, and Beijing. But that's only possible because of our infrastructure — namely our port — and our connections around the world," Bob Harvey, president and CEO of the partnership, said last month. "Houston's ties abroad remain strong."

Houston shopping center opts for buzzy new environmental project

bee's knees

Bees are glorious creatures, tasked with pollination and the no-big-deal duty of balancing our planet's ecosystem and keeping the circle of life moving. Oh, and the honey!

No surprise, then, that beekeeping is all the buzz. With that in mind, a local outlet center is launching its own honeybee colony on its rooftop. Tanger Outlets Houston is taking off with a new pollinator project, and the public is welcome to join and learn about these precious winged buddies. The project is a partnership with Alvéole, a social beekeeping company.

Expect educational bee workshops for retailers and shoppers, meant to reinforce the benefits of urban beekeeping. Resident beekeeper Evan Donoho Gregory will offer a hands-on, interactive experience designed to get shoppers sweet on honeybees and more connected to their environment, per a press release.

Gregory will also make regular visits to the center to maintain and care for the colonies; enthusiasts can follow along on social media.

A little about the hive: it's set up to allow the bees to pollinate the area's flora and thrive within a three-mile radius. At the height of the season, per press materials, each hive will contain up to 50,000 honeybees. That swarm will include some 90 percent worker bees (females) and 10 percent drones (males). Natch, each hive contains one queen bee. (There can be only one!)

With hope, the industrious honeybees will produce the equivalent of 100 jars of hyperlocal, artisanal honey per urban apiary. Tanger Outlets Houston plans to harvest the honey to share with its neighbors, per a release.

"Sharing the city with our winged neighbors is a simple, natural way to positively impact the environment," said Tanger Outlets marketing director Oliver Runco, in a statement. "We're eager to share the buzzworthy details of upcoming workshops that will educate our shoppers, brands and community on the critical role honeybees play in our ecosystem."

Bee fans can watch the progress, check out photos, videos, and upcoming beekeeper visit dates at MyHive Tanger Outlets Houston. For information on upcoming workshops, visit tangeroutlet.com/Houston and follow along on Facebook and Instagram.

------

This article originally ran on CultureMap.